Profile Response Detail

Molecular Profile ERBB2 amp
Therapy Afatinib
Indication/Tumor Type Advanced Solid Tumor
Response Type sensitive
Create By smockus
Update By

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
ERBB2 amp Advanced Solid Tumor sensitive Afatinib Phase II Actionable In a Phase II trial, Gilotrif (afatinib), demonstrated safety and efficacy in various advanced solid tumor patients with ERBB2 (HER2) amplification (PMID: 23775486). 23775486
PubMed Id Reference Title Details
(23775486) Phase 2 trial of afatinib, an ErbB family blocker, in solid tumors genetically screened for target activation. Full reference...